Clinical study on the treatment of chronic gastritis with rabeprazole combined with flupentixol and melitracen
Objective To observe the effect of rabeprazole combined with flupentixol and melitracen in the treatment of patients with chronic gastritis.Methods 100 patients with chronic gastritis were selected,and divided into a control group(treated with rabeprazole)and a study group(treated with rabeprazole+flupentixol and melitracen)by drawing lots,with 50 cases in each group.The treatment effects,relevant scores[Hamilton Depression Scale(HAMD),Hamilton Anxiety Scale(HAMA),Gastrointestinal Symptom Rating Scale(GSRS)score],occurrence of adverse reactions and recurrence were compared between the two groups.Results The total effective rate of the study group was 96.00%,which was higher than the control group's 82.00%(P<0.05).After treatment,the scores of GSRS,HAMD and HAMA in both groups were lower than those before treatment;the scores of GSRS,HAMD and HAMA in the study group were(8.21±0.62),(14.10±0.66)and(13.02±0.51)points,which were lower than(13.22±1.19),(18.79±1.26)and(17.19±0.66)points in the control group(P<0.05).The incidence of adverse reactions in the study group was 8.00%,which was lower than the control group's 24.00%(P<0.05).After 4 months of follow-up,there were no recurrence cases in the study group and 5 recurrent cases with a recurrence rate of 10.00%;the recurrence rate in the study group was lower than that in the control group(x2=5.263,P=0.022<0.05).Conclusion The combination treatment of rabeprazole and flupentixol and melitracen can improve the symptoms and psychological status of patients with chronic gastritis,prevent adverse reactions,reduce the risk of recurrence,and enhance clinical efficacy.It has the value of promotion and application.
Chronic gastritisFlupentixol and melitracenRabeprazoleClinical efficacy
NETL
NSTL
万方数据
